AI Summary & Key Takeaways
AI InsightNone of the morbidly obese patients, who were administrated sugammadexn (2 mg kg-1) via intravenous administration, underwent reoperation in the postoperative period due to coagulopathy.
📌 3 Key Takeaways
Özet
Sugammadex is known to have minimal effects on coagulopathy. The aim of this study was to analyse the changes in platelet levels and platelet-to-lymphocyte ratio (PLR) in preoperative and postoperative periods in morbidly obese patients. This retrospective study included a total of 86 morbidly obese patients with a Body Mass Index (BMI) of >40 kg/m2 and with an American Society of Anaesthesiologists Classification score (ASA) III undergoing elective laparoscopic sleeve gastrectomy (LSG). Patient data were obtained from patient files and electronic health records system (SARUS). The patients were allocated into two groups namely sugammadex (Group S) and neostigmine (Group N). Preoperative and postoperative (12th hour) hemogram recordings of the patients were examined. Compared to preoperative levels, there was a significant decrease in the postoperative platelet and lymphocyte values of patients in Group S (p 0.05). Although sugammadex causes a decrease in the platelet and lymphocyte levels in the postoperative period similar to neostigmine, a relatively higher decrease in lymphocyte levels caused an increase in PLR values. None of the morbidly obese patients, who were administrated sugammadexn (2 mg kg-1) via intravenous administration, underwent reoperation in the postoperative period due to coagulopathy.